Yes, Abilify (aripiprazole) is extensively metabolized by the liver.
Aripiprazole undergoes hepatic metabolism primarily through two cytochrome P450 enzymes: CYP2D6 and CYP3A4. 1 The liver processes aripiprazole through three main biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. CYP3A4 and CYP2D6 are responsible for dehydrogenation and hydroxylation, while CYP3A4 alone catalyzes N-dealkylation 1.
Key Metabolic Characteristics
Elimination route: Following oral administration, approximately 25% of aripiprazole is recovered in urine and 55% in feces, with less than 1% excreted unchanged in urine and approximately 18% recovered unchanged in feces 1. This confirms that hepatic metabolism is the predominant elimination pathway.
Active metabolite: The liver produces dehydro-aripiprazole, an active metabolite that represents about 40% of the parent drug exposure in plasma at steady-state 1. This metabolite has similar affinity for D2 receptors as the parent compound 2.
Half-life considerations: The mean elimination half-life is approximately 75 hours for aripiprazole and 94 hours for dehydro-aripiprazole in normal metabolizers. However, in CYP2D6 poor metabolizers, the half-life extends to about 146 hours 1, demonstrating the critical role of hepatic enzyme activity.
Clinical Implications for Hepatic Impairment
Dose adjustments are generally NOT required for patients with hepatic impairment. Studies show that while total drug concentrations may vary, the free (unbound) drug concentrations and apparent oral clearance (CL/Fu) remain comparable between patients with normal hepatic function and those with mild, moderate, or severe hepatic impairment (Child-Pugh A, B, or C) 3. The fraction of unbound aripiprazole increases in hepatic impairment, compensating for changes in total drug levels 3.
Drug Interaction Considerations
Because aripiprazole depends heavily on hepatic CYP enzymes, significant drug interactions occur with CYP2D6 and CYP3A4 inhibitors or inducers 4, 1:
- Strong CYP2D6 inhibitors (like paroxetine, fluoxetine, or bupropion): Can increase aripiprazole exposure up to 5-fold 5, requiring dose reduction to half the usual dose
- Strong CYP3A4 inhibitors (like ketoconazole, itraconazole): Require dose reduction
- Combined strong inhibitors of both enzymes: Can increase exposure 4.5-fold in extensive metabolizers 1
- CYP3A4 inducers (like carbamazepine, rifampin): May require dose increases
Monitoring Recommendations
While routine dose adjustment isn't needed for hepatic impairment, monitor for adverse effects in patients with liver disease, particularly those on multiple medications that affect CYP enzymes 4. The drug's extensive hepatic metabolism means that liver function changes could theoretically affect drug levels, even though clinical studies haven't demonstrated this consistently 3.
Renal clearance is negligible (approximately 0.04 mL/h/kg), so kidney function doesn't significantly impact aripiprazole elimination 3.